Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor ...

Terns’ pipeline includes three clinical-stage development programs including an allosteric BCR-ABL inhibitor, a small ...

From 2020 to 2023, the number of individuals ages 12 to 25 years who received a prescription for the diabetes or weight-loss ...

A recent study in the Journal of Clinical Medicine found that oral semaglutide significantly improves glycemic control and ...

Popular weight loss drugs like Wegovy and Ozempic have changed the way many Americans are eating and as people taking these ...

E-cigarettes were introduced in the early 2000s as a way for smokers to manage their nicotine addiction without exposing ...

Patients who received CT-388 had an average placebo-adjusted weight loss of 18.8%. CT-388 is well tolerated with only mild to ...

Zealand Pharma’s GLP-1/GLP-2 receptor dual agonist may have only managed at best an average 4.3% reduction in weight loss ...

Tokyo, Japan and Cambridge, UK, 30 May 2024 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) today announced that it expects to receive $4.6 ...

While Eli Lilly and Novo Nordisk currently dominate the GLP-1 receptor agonist space, there are more than 50 candidates in ...

Merck & Co. agrees to acquire Eyebiotech (EyeBio) for up to $3 billion, a deal that will return the buyer to the eye drug ...

Individuals taking glucagon-like peptide (GLP)-1 receptor agonists have a greater risk for subsequently being dispensed ...